An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging

被引:16
作者
Wanet, Marie [1 ]
Delor, Antoine [2 ]
Hanin, Francois-Xavier [3 ]
Ghaye, Benoit [4 ]
Van Maanen, Aline [5 ]
Remouchamps, Vincent [6 ]
Clermont, Christian [6 ]
Goossens, Samuel [1 ]
Lee, John Aldo [1 ]
Janssens, Guillaume [1 ]
Bol, Anne [1 ]
Geets, Xavier [1 ]
机构
[1] Catholic Univ Louvain, Inst Rech Expt & Clin, Ctr Mol Imaging Radiotherapy & Oncol MIRO, Ave Hippocrate,54 Bte B1-54-07, B-1200 Brussels, Belgium
[2] Clin Univ St Luc, Dept Radiat Oncol, B-1200 Brussels, Belgium
[3] Clin Univ St Luc, Dept Nucl Med, B-1200 Brussels, Belgium
[4] Clin Univ St Luc, Dept Radiol, B-1200 Brussels, Belgium
[5] Clin Univ St Luc, Stat Support Unit, Canc Ctr, B-1200 Brussels, Belgium
[6] CHU UCL Namur, Dept Radiat Oncol, Clin & Maternite St Elisabeth Namur, B-5000 Namur, Belgium
关键词
Non-small cell lung cancer; Dose escalation; FDG-PET imaging; Intensity modulated radiotherapy; Toxicity; 3-DIMENSIONAL CONFORMAL RADIOTHERAPY; ELECTIVE NODAL IRRADIATION; NORMAL TISSUE CONSTRAINTS; THERAPY ONCOLOGY GROUP; PHASE-II; CONCURRENT CHEMORADIATION; THORACIC RADIOTHERAPY; RESPONSE EVALUATION; NSCLC PATIENTS; SOLID TUMORS;
D O I
10.1007/s00066-017-1168-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim The aim of the study was to assess the feasibility of an individualized 18F fluorodeoxyglucose positron emission tomography (FDG-PET)-guided dose escalation boost in non-small cell lung cancer (NSCLC) patients and to assess its impact on local tumor control and toxicity. Patients and methods total of 13 patients with stage II-III NSCLC were enrolled to receive a dose of 62.5 Gy in 25 fractions to the CT-based planning target volume (PTV; primary turmor and affected lymph nodes). The fraction dose was increased within the individual PET-based PTV (PTVPET) using intensity modulated radiotherapy (IMRT) with a simultaneous integrated boost (SIB) until the predefined organ-at-risk (OAR) threshold was reached. Tumor response was assessed during follow-up by means of repeat FDG-PET/computed tomography. Acute and late toxicity were recorded and classified according to the CTCAE criteria (Version 4.0). Local progression-free survival was determined using the Kaplan-Meier method. Results The average dose to PTVPET reached 89.17 Gy for peripheral and 75 Gy for central tumors. After a median follow-up period of 29 months, seven patients were still alive, while six had died (four due to distant progression, two due to grade 5 toxicity). Local progression was seen in two patients in association with further recurrences. One and 2-year local progression free survival rates were 76.9% and 52.8%, respectively. Three cases of acute grade 3 esophagitis were seen. Two patients with central tumors developed late toxicity and died due to severe hemoptysis. Conclusion hese results suggest that a non-uniform and individualized dose escalation based on FDG-PET in IMRT delivery is feasible. The doses reached were higher in patients with peripheral compared to central tumors. This strategy enables good local control to be achieved at acceptable toxicity rates. However, dose escalation in centrally located tumors with direct invasion of mediastinal organs must be performed with great caution in order to avoid severe late toxicity.
引用
收藏
页码:812 / 822
页数:11
相关论文
共 53 条
[1]   Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC:: A prospective study [J].
Aerts, Hugo J. W. L. ;
Bosmans, Geert ;
van Baardwijk, Angela A. W. ;
Dekker, Andre L. A. J. ;
Oellers, Michel C. ;
Lambin, Philippe ;
De Ruysscher, Dirk .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 71 (05) :1402-1407
[2]   Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: A prospective validation [J].
Aerts, Hugo J. W. L. ;
Bussink, Johan ;
Oyen, Wim J. G. ;
van Elmpt, Wouter ;
Folgering, Annemieke M. ;
Emans, Daisy ;
Velders, Marije ;
Lambin, Philippe ;
De Ruysscher, Dirk .
LUNG CANCER, 2012, 75 (01) :73-76
[3]   Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer [J].
Auperin, Anne ;
Le Pechoux, Cecile ;
Rolland, Estelle ;
Curran, Walter J. ;
Furuse, Kiyoyuki ;
Fournel, Pierre ;
Belderbos, Jose ;
Clamon, Gerald ;
Ulutin, Hakki Cuneyt ;
Paulus, Rebecca ;
Yamanaka, Takeharu ;
Bozonnat, Marie-Cecile ;
Uitterhoeve, Apollonia ;
Wang, Xiaofei ;
Stewart, Lesley ;
Arriagada, Rodrigo ;
Burdett, Sarah ;
Pignon, Jean-Pierre .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2181-2190
[4]   Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy [J].
Belderbos, Jose S. A. ;
Heemsbergen, Wilma D. ;
De Jaeger, Katrien ;
Baas, Paul ;
Lebesque, Joos V. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (01) :126-134
[5]   From CHART to CHARTWEL in non-small cell lung cancer: Clinical radiobiological modelling of the expected change in outcome [J].
Bentzen, SM ;
Saunders, MI ;
Dische, S .
CLINICAL ONCOLOGY, 2002, 14 (05) :372-381
[6]   Standardised FDG uptake: A prognostic factor for inoperable non-small cell lung cancer [J].
Borst, GR ;
Belderbos, JSA ;
Boellaard, R ;
Comans, EFI ;
De Jaeger, K ;
Lammertsma, AA ;
Lebesque, JV .
EUROPEAN JOURNAL OF CANCER, 2005, 41 (11) :1533-1541
[7]   Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma [J].
Bradley, J ;
Graham, MV ;
Winter, K ;
Purdy, JA ;
Komaki, R ;
Roa, WH ;
Ryu, JK ;
Bosch, W ;
Emami, B .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (02) :318-328
[8]   Elective nodal failures are uncommon in medically inoperable patients with Stage I non-small-cell lung carcinoma treated with limited radiotherapy fields [J].
Bradley, JD ;
Wahab, S ;
Lockett, MA ;
Perez, CA ;
Purdy, JA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (02) :342-347
[9]   Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study [J].
Bradley, Jeffrey D. ;
Paulus, Rebecca ;
Komaki, Ritsuko ;
Masters, Gregory ;
Blumenschein, George ;
Schild, Steven ;
Bogart, Jeffrey ;
Hu, Chen ;
Forster, Kenneth ;
Magliocco, Anthony ;
Kavadi, Vivek ;
Garces, Yolanda I. ;
Narayan, Samir ;
Iyengar, Puneeth ;
Robinson, Cliff ;
Wynn, Raymond B. ;
Koprowski, Christopher ;
Meng, Joanne ;
Beitler, Jonathan ;
Gaur, Rakesh ;
Curran, Walter, Jr. ;
Choy, Hak .
LANCET ONCOLOGY, 2015, 16 (02) :187-199
[10]   A PHASE I/II RADIATION DOSE ESCALATION STUDY WITH CONCURRENT CHEMOTHERAPY FOR PATIENTS WITH INOPERABLE STAGES I TO III NON-SMALL-CELL LUNG CANCER: PHASE I RESULTS OF RTOG 0117 [J].
Bradley, Jeffrey D. ;
Moughan, Jennifer ;
Graham, Mary V. ;
Byhardt, Roger ;
Govindan, Ramaswamy ;
Fowler, Jack ;
Purdy, James A. ;
Michalski, Jeff M. ;
Gore, Elizabeth ;
Choy, Hak .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 77 (02) :367-372